AIMS/HYPOTHESIS: Type 2 diabetes is associated with reduced antioxidant defence. Only a few human studies have investigated the role of antioxidants in the pathogenesis of diabetes. This study aimed to examine whether alpha-tocopherol or beta-carotene affected the occurrence of type 2 diabetes. METHODS: In the Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study, a double-blind, controlled trial, 29,133 male smokers aged 50-69 years were randomised to receive either alpha-tocopherol (50 mg/day) or beta-carotene (20 mg/day) or both agents or placebo daily for 5-8 years (median 6.1 years). Baseline serum samples were analysed for alpha-tocopherol and beta-carotene using HPLC. Cases of diabetes were identified from a nationwide Finnish registry of patients receiving drug reimbursement for diabetes. Of 27,379 men without diabetes at baseline, 705 men were diagnosed with diabetes during the follow-up of up to 12.5 years. RESULTS:Baseline serum levels of alpha-tocopherol and beta-carotene were not associated with the risk of diabetes in the placebo group: the relative risk (RR) between the highest and lowest quintiles of alpha-tocopherol was 1.59 (95% CI 0.89-2.84) and that for beta-carotene was 0.66 (95% CI 0.40-1.10). Neither supplementation significantly affected the incidence of diabetes: the RR was 0.92 (95% CI 0.79-1.07) for participants receiving alpha-tocopherol compared with non-recipients and 0.99 (95% CI 0.85-1.15) for participants receiving beta-carotene compared with non-recipients. CONCLUSIONS/ INTERPRETATION: Neither alpha-tocopherol nor beta-carotene supplementation prevented type 2 diabetes in male smokers. Serum levels of alpha-tocopherol and beta-carotene were not associated with the risk of type 2 diabetes.
RCT Entities:
AIMS/HYPOTHESIS: Type 2 diabetes is associated with reduced antioxidant defence. Only a few human studies have investigated the role of antioxidants in the pathogenesis of diabetes. This study aimed to examine whether alpha-tocopherol or beta-carotene affected the occurrence of type 2 diabetes. METHODS: In the Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study, a double-blind, controlled trial, 29,133 male smokers aged 50-69 years were randomised to receive either alpha-tocopherol (50 mg/day) or beta-carotene (20 mg/day) or both agents or placebo daily for 5-8 years (median 6.1 years). Baseline serum samples were analysed for alpha-tocopherol and beta-carotene using HPLC. Cases of diabetes were identified from a nationwide Finnish registry of patients receiving drug reimbursement for diabetes. Of 27,379 men without diabetes at baseline, 705 men were diagnosed with diabetes during the follow-up of up to 12.5 years. RESULTS: Baseline serum levels of alpha-tocopherol and beta-carotene were not associated with the risk of diabetes in the placebo group: the relative risk (RR) between the highest and lowest quintiles of alpha-tocopherol was 1.59 (95% CI 0.89-2.84) and that for beta-carotene was 0.66 (95% CI 0.40-1.10). Neither supplementation significantly affected the incidence of diabetes: the RR was 0.92 (95% CI 0.79-1.07) for participants receiving alpha-tocopherol compared with non-recipients and 0.99 (95% CI 0.85-1.15) for participants receiving beta-carotene compared with non-recipients. CONCLUSIONS/ INTERPRETATION: Neither alpha-tocopherol nor beta-carotene supplementation prevented type 2 diabetes in male smokers. Serum levels of alpha-tocopherol and beta-carotene were not associated with the risk of type 2 diabetes.
Authors: Eva Lonn; Salim Yusuf; Byrcon Hoogwerf; Janice Pogue; Qilong Yi; Bernard Zinman; Jackie Bosch; Gilles Dagenais; Johannes F E Mann; Hertzel C Gerstein Journal: Diabetes Care Date: 2002-11 Impact factor: 19.112
Authors: H Ylihärsilä; J Lindström; J G Eriksson; P Jousilahti; T T Valle; J Sundvall; J Tuomilehto Journal: Diabet Med Date: 2005-01 Impact factor: 4.359
Authors: J R B Perry; L Ferrucci; S Bandinelli; J Guralnik; R D Semba; N Rice; D Melzer; R Saxena; L J Scott; M I McCarthy; A T Hattersley; E Zeggini; M N Weedon; T M Frayling Journal: Diabetologia Date: 2009-08-07 Impact factor: 10.122
Authors: May A Beydoun; J Atilio Canas; Hind A Beydoun; Xiaoli Chen; Monal R Shroff; Alan B Zonderman Journal: J Nutr Date: 2012-07-18 Impact factor: 4.798
Authors: Merja Kataja-Tuomola; Jari Sundell; Satu Männistö; Mikko J Virtanen; Jukka Kontto; Demetrius Albanes; Jarmo Virtamo Journal: Eur J Epidemiol Date: 2010-03-30 Impact factor: 8.082
Authors: May A Beydoun; Monal R Shroff; Xiaoli Chen; Hind A Beydoun; Youfa Wang; Alan B Zonderman Journal: J Nutr Date: 2011-03-30 Impact factor: 4.798
Authors: J Arnlöv; B Zethelius; U Risérus; S Basu; C Berne; B Vessby; G Alfthan; J Helmersson Journal: Diabetologia Date: 2008-11-05 Impact factor: 10.122